These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16842375)

  • 1. Drug development in oncology: classical cytotoxics and molecularly targeted agents.
    Kummar S; Gutierrez M; Doroshow JH; Murgo AJ
    Br J Clin Pharmacol; 2006 Jul; 62(1):15-26. PubMed ID: 16842375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
    Le Tourneau C; Diéras V; Tresca P; Cacheux W; Paoletti X
    Target Oncol; 2010 Mar; 5(1):65-72. PubMed ID: 20361265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted agents: how to select the winners in preclinical and early clinical studies?
    Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
    Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
    Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
    Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target selection issues in drug discovery and development.
    Sausville EA
    J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current stumbling blocks in oncology drug development.
    Gimmi CD
    Ernst Schering Res Found Workshop; 2007; (59):135-49. PubMed ID: 17117720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman RA
    Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation methods in phase I cancer clinical trials.
    Le Tourneau C; Lee JJ; Siu LL
    J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials.
    Burczynski ME; Oestreicher JL; Cahilly MJ; Mounts DP; Whitley MZ; Speicher LA; Trepicchio WL
    Curr Mol Med; 2005 Feb; 5(1):83-102. PubMed ID: 15720272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
    Bullock JM; Rahman A; Liu Q
    Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The true face of the revolution in oncology drug development: a personal reflection.
    Burgess M; de Alwis DP
    Curr Clin Pharmacol; 2007 Jan; 2(1):31-5. PubMed ID: 18690853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.